Spots Global Cancer Trial Database for recurrent melanoma
Every month we try and update this database with for recurrent melanoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors | NCT00667641 | Breast Cancer Colorectal Canc... Head and Neck C... Lung Cancer Melanoma (Skin) Ovarian Cancer Pancreatic Canc... Prostate Cancer Unspecified Adu... | bortezomib paclitaxel | 18 Years - | Rutgers, The State University of New Jersey | |
| Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer | NCT00004135 | Kidney Cancer Melanoma (Skin) | filgrastim therapeutic all... cyclophosphamid... fludarabine pho... peripheral bloo... | 18 Years - 65 Years | University of Chicago | |
| Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma | NCT00091143 | Melanoma (Skin) | gp100 antigen incomplete Freu... keyhole limpet ... fludarabine pho... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma | NCT00053781 | Melanoma (Skin) | perifosine | 18 Years - 120 Years | Canadian Cancer Trials Group | |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00056134 | Melanoma (Skin) | Dendritic cell ... | 18 Years - 120 Years | University Hospital Erlangen | |
| BMS-247550 in Treating Patients With Stage IV Melanoma | NCT00036764 | Recurrent Melan... Stage IV Melano... | ixabepilone pharmacogenomic... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | NCT00089193 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim | 12 Years - | University of Virginia | |
| Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00007969 | Melanoma (Skin) | Detox-B adjuvan... verteporfin | 18 Years - | National Cancer Institute (NCI) | |
| Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma | NCT00514085 | Melanoma (Skin) | recombinant hum... immunohistochem... laboratory biom... pharmacological... | 18 Years - | Canadian Cancer Trials Group | |
| A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma | NCT03153085 | Melanoma Stage ... Melanoma Stage ... | TBI-1401(HF10) Ipilimumab | 20 Years - | Takara Bio Inc. | |
| Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib | NCT01519427 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | Akt inhibitor M... selumetinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | NCT00110019 | Mucosal Melanom... Recurrent Melan... Stage IIIA Skin... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M... | Carboplatin Laboratory Biom... Paclitaxel Pharmacological... Placebo Sorafenib Tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Metastatic Melanoma | NCT00045149 | Melanoma (Skin) | aldesleukin therapeutic tum... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma | NCT00081042 | Melanoma (Skin) | paclitaxel albu... | 18 Years - | National Cancer Institute (NCI) | |
| Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | NCT01708941 | Recurrent Melan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... | Ipilimumab Laboratory Biom... Recombinant Int... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma | NCT00002669 | Melanoma (Skin) | aldesleukin recombinant int... cisplatin dacarbazine | 18 Years - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | NCT00003222 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... sargramostim tetanus peptide... tyrosinase pept... | 18 Years - 79 Years | University of Virginia | |
| Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery | NCT02013492 | Male Breast Can... Recurrent Melan... Stage IV Breast... Stage IV Melano... Stage IV Ovaria... Stage IV Ovaria... Unspecified Adu... Hepatocellular ... | propranolol hyd... Correlative Stu... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma | NCT00005057 | Melanoma (Skin) | adenovirus RSV-... ganciclovir | 18 Years - | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer | NCT00020540 | Kidney Cancer Melanoma (Skin) | recombinant CD4... recombinant flt... | 16 Years - | National Cancer Institute (NCI) | |
| PS-341 in Treating Patients With Metastatic Malignant Melanoma | NCT00024011 | Recurrent Melan... Stage IV Melano... | bortezomib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma | NCT00077532 | Melanoma (Skin) | gp100 antigen incomplete Freu... ipilimumab | 16 Years - | National Institutes of Health Clinical Center (CC) | |
| Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery | NCT00450372 | Melanoma (Skin) | ADI-PEG-20 Pharmacology St... | 18 Years - 120 Years | University of Miami | |
| Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | NCT01961115 | Mucosal Melanom... Recurrent Melan... Recurrent Uveal... Stage IIIA Skin... Stage IIIA Uvea... Stage IIIB Skin... Stage IIIB Uvea... Stage IIIC Skin... Stage IIIC Uvea... Stage IV Skin M... Stage IV Uveal ... | Epacadostat MELITAC 12.1 Pe... | 18 Years - | Fred Hutchinson Cancer Center | |
| Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | NCT00387751 | Recurrent Melan... Stage III Skin ... Stage IV Skin M... | Bevacizumab Laboratory Biom... Pharmacological... Sorafenib Tosyl... | 18 Years - 120 Years | National Cancer Institute (NCI) | |
| Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors | NCT00112476 | Recurrent Melan... Recurrent Renal... Stage IV Melano... Stage IV Renal ... Unspecified Adu... | bryostatin 1 temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma | NCT00062036 | Melanoma (Skin) | aldesleukin filgrastim incomplete Freu... interleukin-2 g... therapeutic tum... cyclophosphamid... fludarabine pho... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma | NCT00074230 | Melanoma (Skin) | Autologous Dend... | 18 Years - | University Hospital Erlangen | |
| Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | NCT00004025 | Melanoma (Skin) | aldesleukin dendritic cell-... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00019994 | Melanoma (Skin) | MART-1 antigen aldesleukin gp100 antigen incomplete Freu... | 16 Years - | National Cancer Institute (NCI) | |
| Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer | NCT00492440 | Kidney Cancer Melanoma (Skin) | recombinant int... gene expression... polymerase chai... protein express... flow cytometry immunoenzyme te... immunologic tec... laboratory biom... pharmacological... | 18 Years - | Cytheris SA | |
| Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma | NCT00004244 | Kidney Cancer Melanoma (Skin) | recombinant int... recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma | NCT00512798 | Brain and Centr... Melanoma Solid Tumor | PS-341 (VELCADE... temozolomide immunoenzyme te... PS-341 (VELCADE... Temozolomide | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| 0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma | NCT00729807 | Melanoma (Skin) | pentamidine | 18 Years - 120 Years | University of Maryland, Baltimore | |
| Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma | NCT00002892 | Melanoma (Skin) | recombinant int... | - | National Cancer Institute (NCI) | |
| BMS-247550 in Treating Patients With Stage IV Melanoma | NCT00036764 | Recurrent Melan... Stage IV Melano... | ixabepilone pharmacogenomic... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma | NCT00471887 | Melanoma (Skin) | CP-675,206 | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma | NCT00324623 | Melanoma (Skin) | Melan-A VLP vac... adoptive immuno... therapeutic aut... cyclophosphamid... fludarabine pho... | 18 Years - 75 Years | Centre Hospitalier Universitaire Vaudois | |
| Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy | NCT00897481 | Melanoma (Skin) | gene expression... mutation analys... diagnostic labo... immunohistochem... sentinel lymph ... | - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00085397 | Melanoma (Skin) | autologous dend... gp100 antigen therapeutic aut... | - | National Cancer Institute (NCI) | |
| Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00004184 | Melanoma (Skin) | monoclonal anti... sargramostim alum adjuvant | 18 Years - | University of Alabama at Birmingham | |
| High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma | NCT00003091 | Kidney Cancer Melanoma (Skin) | aldesleukin recombinant int... | 18 Years - | Hoag Memorial Hospital Presbyterian | |
| Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma | NCT01744171 | Recurrent Melan... Stage IIIB Skin... Stage IIIC Skin... Stage IV Skin M... | Recombinant Hum... Laboratory Biom... | 18 Years - | Roswell Park Cancer Institute | |
| Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma | NCT00357461 | Melanoma (Skin) | gp100:209-217(2... gp100:280-288(2... incomplete Freu... ipilimumab | 16 Years - | Bristol-Myers Squibb | |
| Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma | NCT01970527 | Recurrent Melan... Stage IV Skin M... | Ipilimumab Laboratory Biom... Pharmacological... Stereotactic Bo... | 18 Years - | University of Washington | |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | NCT00089193 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim | 12 Years - | University of Virginia | |
| Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | NCT00550654 | Kidney Cancer Melanoma (Skin) Metastatic Canc... Ovarian Cancer Sarcoma Unspecified Adu... | questionnaire a... 3-dimensional c... hypofractionate... image-guided ra... tomotherapy | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy | NCT00897481 | Melanoma (Skin) | gene expression... mutation analys... diagnostic labo... immunohistochem... sentinel lymph ... | - | National Cancer Institute (NCI) | |
| Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma | NCT00602576 | Melanoma (Skin) | sorafenib tosyl... temozolomide | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma | NCT00003895 | Recurrent Melan... Stage IA Melano... Stage IB Melano... Stage IIA Melan... Stage IIB Melan... Stage IIC Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... | HPV 16 E7:12-20 gp100:209-217(2... laboratory biom... | 17 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00003346 | Melanoma (Skin) | acetaminophen acetylcysteine carmustine | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusion in Treating Patients With Stage IV Melanoma | NCT00006233 | Melanoma (Skin) | therapeutic all... cyclosporine fludarabine pho... mycophenolate m... peripheral bloo... radiation thera... | 18 Years - 64 Years | Fred Hutchinson Cancer Center | |
| Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma | NCT00436605 | Recurrent Melan... Stage IIIA Mela... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | dasatinib | 18 Years - | National Cancer Institute (NCI) | |
| Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma | NCT00863330 | Melanoma (Skin) | Tumor Infiltrat... | 18 Years - | Aurora Health Care | |
| PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma | NCT00049530 | Melanoma (Skin) | PEG-interferon ... | 18 Years - | Eastern Cooperative Oncology Group | |
| Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial | NCT00316901 | Kidney Cancer Melanoma (Skin) | computed tomogr... positron emissi... fludeoxyglucose... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma | NCT01339663 | Recurrent Melan... Stage IV Melano... | cyclophosphamid... aldesleukin autologous tumo... laboratory biom... immunologic tec... immunohistochem... polymerase chai... therapeutic aut... | 18 Years - | Fred Hutchinson Cancer Center | |
| Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | NCT00404235 | Melanoma (Skin) | carboplatin paclitaxel albu... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma | NCT00863330 | Melanoma (Skin) | Tumor Infiltrat... | 18 Years - | Aurora Health Care | |
| Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Responded to Previous Treatment | NCT00022438 | Melanoma (Skin) | aldesleukin incomplete Freu... recombinant tyr... | 16 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma | NCT01307618 | Recurrent Melan... Stage IV Skin M... | NA17.A2 Peptide... Recombinant MAG... Recombinant Int... MART-1 Antigen Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery | NCT00281957 | Recurrent Melan... Stage IV Melano... | sorafenib tosyl... tipifarnib temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Tipifarnib in Treating Patients With Metastatic Malignant Melanoma | NCT00060125 | Recurrent Melan... Stage IV Melano... | tipifarnib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | NCT04514484 | Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi... | Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal | NCT00003229 | Melanoma (Skin) | aldesleukin gp100 antigen tyrosinase pept... | 18 Years - 75 Years | Duke University | |
| E7070 in Treating Patients With Stage IV Melanoma | NCT00014625 | Melanoma (Skin) | indisulam | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma | NCT00301067 | Metastatic Mela... | Calcitriol Temozolomide | 18 Years - | Northwestern University | |
| Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer | NCT00253708 | Cancer | management of t... massage therapy pain therapy psychosocial as... quality-of-life... | 18 Years - 120 Years | Beth Israel Deaconess Medical Center | |
| Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | NCT01851408 | Melanoma Recurrent Melan... Stage III Melan... Stage IV Melano... | sorafenib tosyl... temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma | NCT00553306 | Recurrent Melan... Stage IV Melano... | therapeutic aut... aldesleukin cyclophosphamid... biopsy immunohistochem... flow cytometry polymerase chai... | 18 Years - 75 Years | Fred Hutchinson Cancer Center | |
| MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma | NCT00866177 | Recurrent Melan... Stage III Skin ... Stage IV Skin M... | Laboratory Biom... Selumetinib | 18 Years - | National Cancer Institute (NCI) | |
| Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer | NCT00492440 | Kidney Cancer Melanoma (Skin) | recombinant int... gene expression... polymerase chai... protein express... flow cytometry immunoenzyme te... immunologic tec... laboratory biom... pharmacological... | 18 Years - | Cytheris SA | |
| Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | NCT00089362 | Male Breast Can... Recurrent Adeno... Recurrent Basal... Recurrent Breas... Recurrent Colon... Recurrent Esthe... Recurrent Gastr... Recurrent Inver... Recurrent Lymph... Recurrent Lymph... Recurrent Melan... Recurrent Metas... Recurrent Midli... Recurrent Mucoe... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Saliv... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Squam... Recurrent Verru... Recurrent Verru... Stage III Adeno... Stage III Basal... Stage III Colon... Stage III Esthe... Stage III Gastr... Stage III Inver... Stage III Lymph... Stage III Lymph... Stage III Melan... Stage III Midli... Stage III Mucoe... Stage III Ovari... Stage III Renal... Stage III Saliv... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Squam... Stage III Verru... Stage III Verru... Stage IIIB Brea... Stage IIIC Brea... Stage IV Adenoi... Stage IV Basal ... Stage IV Breast... Stage IV Colon ... Stage IV Esthes... Stage IV Gastri... Stage IV Invert... Stage IV Lympho... Stage IV Lympho... Stage IV Melano... Stage IV Midlin... Stage IV Mucoep... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Saliva... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Squamo... Stage IV Verruc... Stage IV Verruc... Unspecified Adu... Untreated Metas... | alvespimycin hy... laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma | NCT00060333 | Recurrent Melan... | radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System | NCT00068666 | Melanoma (Skin) Metastatic Canc... | temozolomide radiation thera... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma | NCT00658892 | Melanoma (Skin) | B7-DC cross-lin... flow cytometry immunologic tec... laboratory biom... | 18 Years - 120 Years | Mayo Clinic | |
| Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00002767 | Melanoma (Skin) | Detox-B adjuvan... recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00091338 | Melanoma (Skin) | MART-1 antigen gp100 antigen incomplete Freu... recombinant int... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma | NCT00303836 | Recurrent Melan... Stage IV Melano... | cyclophosphamid... fludarabine pho... therapeutic aut... in vitro-treate... gp100 antigen MART-1 antigen incomplete Freu... filgrastim aldesleukin | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00002817 | Melanoma (Skin) | sargramostim vaccinia-GM-CSF... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
